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1. Introduction
Deoxyribonucleic acid, DNA,1–3 is a natural product
of an enormous importance for understanding the mecha-
nism of genetic processes such as growth, differentiation
and aging of the cell. Binding of small organic and inorga-
nic molecules to DNA can influence numerous biological
processes in which DNA participate, like transcription
and replication.2,3 These processes begin when DNA re-
ceives the signal from regulatory protein which binds to
its particular part. If, instead of the regulatory protein, so-
me other small molecule binds to DNA, its function is ar-
tificially changed – inhibited or activated. Such interferen-
ce can retard or even prevent the cell growth, or, on the ot-
her hand, it can lead to excessive production of some pro-
tein and uncontrolled cell growth. In the case when the ac-
tivation or inhibition of the DNA function act in the way
to cure or control the disease, small molecule is denoted
as a drug, but otherwise it is cytotoxic agents. Accor-
dingly, the growing interest in studying the process of in-
teraction between DNA and chemotherapeutic drugs is
understandable. Extensive chemical and biochemical stu-
dies have characterised a variety of molecules that react
with DNA, which are classified as antibiotic, antitumor,
antiviral or antiprotozoal agents. Some of them are used in
clinical practice, while the others are still under clinical
trial.
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When the complex between small molecule and
DNA is formed, both molecule, as well as DNA, expe-
rienced some modifications. Detection and explanation of
these changes makes a great challenge for new instrumen-
tal methods. The development of crystallographic and
NMR methods4–6 in the last twenty years made it possible
to ascertain more about the conformational flexibility of
DNA molecule, the influence of base sequence, and the
role of water molecules and counterions. The challenge to
obtain the similar information about DNA–drug comple-
xes arise. The aim of the contemporary research is to di-
stinguish the rules governing sequence specific binding,
to understand the correlation between DNA structure, se-
quence and activity, to determine drug binding sites, as
well as conformational changes due to the DNA–drug in-
teraction. These facts are useful for DNA–drug interaction
mechanism elucidation, what leads to rational drug de-
sign, and development of new anticancer agents.
The intention of this review is to give an overview of
the present state of the DNA–drug interaction cognition.
The presented results summarize literature data obtained
by the application of selected optical and electrochemical
methods, their operation and detection principles. In order
to facilitate the discussion about the stability of obtained
complexes and the modes of the binding interactions, a
brief introduction to the DNA chemical structure should
be considered. 
2. Structural Characteristics 
of DNA Molecule
Deoxyribonucleic acid, DNA,1–3 consists of two
long polynucleotide chains composed of four types of
nucleotide subunits. The nucleotides themselves are com-
posed of a five-carbon sugar (deoxyribose) to which one
or more phosphate groups and a nitrogen-containing base
are attached. Base may be either adenine (A), cytosine
(C), guanine (G), or thymine (T). The nucleotides are co-
valently linked together in a chain through the sugars and
phosphates, which thus form a “backbone” of alternating
sugar and phosphate (Figure 1). The way in which the
Figure 1. Structure of double stranded DNA. Squares denote electroactive groups that can be reduced at mercury electrodes, and circles show sites
oxidized at carbon electrodes.
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nucleotide subunits are lined together gives a polarity to a
DNA strand. If each sugar is presented as a block with a
protruding top (the 5’ phosphate) on one side and a hole
(the 3’ hydroxyl) on the other, each completed chain, for-
med by interlocking tops with holes, will have all of its
subunits lined up in the same orientation. Moreover, the
two ends of the chain will be easily distinguishable, as one
has a hole (the 3’ hydroxyl) and the other a top (the 5’
phosphate) at its terminus. This polarity in a DNA chain is
indicated by referring to one end as the 3’ end and the ot-
her as the 5’ end. The DNA secondary structure is repre-
sented by the double helix which consists of two antipa-
rallel polynucleotide chains that are held together by
hydrogen bonding between the bases of the different
strands, with all the bases on the inside of the double he-
lix, and the sugar-phosphate backbones are on the outside.
This complementary base-pairing enables the base pairs
to be packed in the energetically most favourable arrange-
ment in the interior of the double helix and each strand of
a DNA molecule contains a sequence of nucleotides that
is exactly complementary to the nucleotide sequence of its
partner strand. Parts of a DNA molecule that can interact
with small molecules are: negatively charged phosphate
backbone (electrostatic interaction), the hydrogen accep-
ting and donating sites in the minor and major grooves (H-
bonds), the phosphate oxygen atoms and aromatic hydrop-
hobic components (van der Waals interactions). One
should always keep in mind that DNA is polymorphic, and
the geometry of double helix, including the depth and
width of the minor and major grooves, is different in diffe-
rent conformations (A, B and Z form). Besides, hydration
plays very important role in the stability of DNA molecule,
as well as DNA–drug complex, since this process is belie-
ved to be governing by the base sequence, also.
3. Modes of DNA–drug Interactions
Large number of drug substances, inorganic and or-
ganic, both natural and synthetic, are able to form comple-
xes with DNA molecules, mostly when DNA is in double
stranded form. Drugs interact with DNA molecule both
covalently and non-covalently.
Covalent binding in DNA is irreversible and undoub-
tedly leads to complete inhibition of DNA functions and
subsequent cell death. A major advantage of covalent bin-
ders is the high binding strength. Moreover, covalent
bulky adducts can cause DNA backbone distortion, which
in turn can affect both transcription and replication, by di-
srupting protein complex recruitment.7 Three modes of
covalent binding to DNA are possible: replacement of ni-
trogenous bases, inter and intra-strand cross linking and
alkylation of nitrogenous bases.
The most famous covalent binder is cisplatin (Table
1), which is used as an anticancer drug. When used for cli-
nical practice, cisplatin is administered intravenously. In
the extracellular environment, where the chloride concen-
tration is high, it does not undergo appreciable hydrolysis.
When cisplatin passes the cell membrane the reduced in-
tracellular chloride concentration allows the chlorido li-
gands to be replaced by water molecules to form cis-
[Pt(H2O)(NH3)2Cl]+ and cis-[Pt(H2O)2(NH3)2] 2+. It is
generally accepted that these two cations bind covalently
to the electron-rich sites on DNA such as N-donor li-
gands.8 The preferred target in DNA is guanine (G) since
it has the highest electron density of all four nucleobases.9
It is believed that this reaction is responsible for the anti-
cancer effect of cisplatin which is able to induce apopt-
sis/necrosis of the cancer cell.10
Besides cisplatin, another two antitumor antibiotics
found the application in clinical practise: mitomycin C
and anthramycin (Table 1). Mitomycin C interacts cova-
lently with guanine base only in reduced state, i.e., after
the reductive activation. The activated antibiotic forms a
cross-linking structure between guanine bases on adjacent
strands of DNA thereby inhibiting single strand forma-
tion. Anthramycin covalently binds to N2 nitrogen of gua-
nine, placed in the minor groove of DNA molecule. 
Another type of covalent binders are called alkyla-
ting agents. These agents are capable of adduct formation
by attaching an alkyl group to DNA.11 Alkylating drugs,
like temozolomide, chlorambucil and nimustine are the
oldest class of anticancer drugs but still commonly used in
the treatment of several types of cancers.
Non-covalent binding of drugs to DNA is reversible, and
considering drug metabolism and potential toxic effects, it
is more desirable comparing to covalent. However, non-
covalent DNA interacting agents can change DNA confor-
mation, DNA torsional tension, interrupt protein–DNA in-
teraction, and potentially lead to DNA strand breaks. One
of the main principles of DNA chemistry is molecular re-
cognition, the process when molecules (small or large) se-
lectively recognize each other. This is manifested through
a couple of interaction modes: electrostatic, hydrogen
bonds, and van der Waals (dipole–dipole) interaction. The
stability of the formed complex DNA–drug depends on
the intensity of the mentioned interactions.
Drugs that react non-covalently with DNA are clas-
sified in following categories:12
1. Intercalating agents
2. Minor groove binders
3. Major groove binders
4. External binders
3. 1. Intercalators
Intercalators are molecules that stack perpendicular
to the DNA backbone without forming covalent bonds
and without breaking up the hydrogen bonds between the
DNA bases. The only known forces that sustain the stabi-
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lity of the DNA–intercalator complex, even more than
DNA alone, are van der Waals, hydrogen bonding,
hydrophobic, and/or charge transfer forces.13–17 Intercala-
tion stabilizes, lengthens, stiffens, and unwinds the DNA
double helix.18 Intercalators contain planar heterocyclic
groups which stack between adjacent DNA base pairs,
forming complex which is stabilized by π–π stacking inte-
ractions between the drug and DNA. Intercalators can be
mono- or bifunctional, depending on the number of aro-
matic moieties. There are simple mono-intercalators like
acridine derivatives: proflavine, acriflavine, acriflavine
neutral (euflavine), aminacrine, ethacridine, and more
Table 1. Drugs interacting with DNA, covalently and non-covalently
Drugs that covalently bind to DNA
Cisplatin Mitomycin C Anthramycin
Drugs that non-covalently bind to DNA
Mono-intercalators Bifunctional intercalators
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complex like daunomycin and adriamycin, with four fu-
sed six membered rings with substituents in positions 7
and 9 (Table 1). These intercalators are often called the
threading intercalators since they thread one of the substi-
tuents on opposite sides of the intercalating aromatic ring
between the base pairs at the intercalation site.
In bifunctional intercalators, two planar aromatic
moieties are present and separated by some voluminous
system like fairly rigid cyclic peptide system stabilized
through disulphide bridge as in the case of triostin A and
echinomycin (Table 1.)
The phenomenon of intercalating involves the aro-
matic part of a drug molecule positioning itself between
base pairs (Figure 2). Intercalating agents inure in hydrop-
hobic interactions with DNA because the hydrophobic,
aromatic side chains interact favourably with the aromatic
environment of the base pairs. These agents introduce
strong structural perturbations in DNA molecule by in-
creasing the distance between the adjacent base pairs. In
order for an intercalator to fit between base pairs, the
DNA must dynamically open a space between its base
pairs. Fortunately, the resultant helix distortion is com-
pensated by adjustments in the sugar-phosphate backbone
unwinding of the duplex. Stacking interactions between
the bases and the intercalating molecule are the major sta-
bilising factors for the complex formed. For example, the-
re are direct hydrogen bonds between the functional
groups of the drug that are essential for the drug action (li-
ke hydroxyl group of the ring A or NH3
+ group in the 3’
position in daunomycin) and functional groups N2 and N3
of guanine, or O2 of cytosine at the intercalation site. Very
often, water-mediated contacts occur rather than a direct
hydrogen bonded interaction. Anyway, the total amount of
surface bound water is reduced after the complex forma-
tion. Besides this general scheme of complex formation,
the interaction between the DNA and drug also depends
on the sequence of the bases adjacent to the intercalation
site, and on the chemical modifications of the intercala-
ting drug.
Bifunctional intercalators are able to intercalate in
DNA molecule in two different ways: I – intramolecular
cross-linking, when both aromatic moieties intercalate
with the same DNA molecule, and II – intremolecular
cross-linking, when intercalating moieties interact with
two separate DNA molecules (Figure 2).
There are also multi-intercalators containing three
or more intercalation rings, which were synthesized be-
cause, as potential drugs, their high DNA binding con-
stants are expected to enhance their therapeutic activity.
3. 2. Minor Groove Binders
The most famous minor groove binding drugs are
netropsin, berenil, distamycin and mithramycin (Table 1).
They usually have crescent shape, which complements the
shape of the groove19,20 and facilitates binding by promo-
ting van der Waals interactions. These drugs typically ha-
ve several aromatic rings, such as pyrrole, furan or benze-
ne connected by bonds possessing torsional freedom. Ad-
ditionally, these drugs can form hydrogen bonds to bases,
typically to adenine/thymine rich sequences. In all com-
plexes the drug fits snugly into the minor groove and dis-
places the hydration layer. Thus, it might be expected that
there is relatively little change in DNA itself due to the
complexation, but the results indicates that this is not the
case. In complex structure alternation of the helical twist
is reversed from the uncomplexed alternating DNA. One
of the bases rotates to allow hydrogen bonding to the
drug. Sometimes hydrogen bonding is mediated by a wa-
ter molecule between the drug molecules and the DNA ac-
ting as a major complex stabilising force. Van der Waals
forces also significantly contribute to the stabilisation of
the complexes and may lead to serious perturbations of
the DNA helix from the normal Watson/Crick geometry.
Beyond the changes in DNA, these interactions also
induce changes in the conformation of the groove binding
drugs themselves.
3. 3. Major Groove Binders
Most of the DNA groove binding drugs chose minor
groove as a target. These drugs are generally arc shaped,
planar and unfused aromatic with a positive electrostatic
potential that attracts them to the electronegative potential
of the minor groove, and the arc matching the curvature of
the DNA double helix. Considerably small number of
substances is reported to bind to major groove. The reason
for this probably lies in the fact that nitrogen and oxygen
atoms in base pairs of wide and deep major groove are
oriented towards the axis of the helix, what makes them
accessible for proteins.21 Proteins recognize these base se-
quences, and specific binding interaction takes place. In
Figure 2. Types of intercalation of bifunctional intercalators in
DNA molecule: I - intramolecular cross-link and II - intermolecular
cross-link.
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order to inhibit these protein–DNA interactions it was ne-
cessary to find natural products or to design ligands that
will act as a major groove binding agents. 
First, solid evidence about the small molecules
(methyl green) binding to major groove dates from
1993.22 Later on some antitumor agents with acridine car-
boxamide skeleton,21 aminoglycoside antibiotics to-
bramycin, and other agents as pluramyicins, aflatoxins,
azinomycins, and neocarzinostatin were synthesized.23,24
Unfortunately, number of these drugs is still very modest.
A better understanding of DNA–ligand chemical interac-
tions is necessary for the rational design of more efficient
analogues as potential DNA major groove binding drugs. 
3. 4. External Binders 
This type of binding is electrostatic in nature. Some
ligands are capable of forming non-specific, outside edge
stacking interactions with the DNA phosphate backbone.
This mode usually occurs when the ligand self-associates
to form higher-order aggregates, which may stack on the
anionic DNA backbone in order to reduce charge–charge
repulsion between ligand molecules. Some metal comple-
xes interact with DNA through external binding. This as-
sociation mode was proposed for [Ru(bpy)3]2+ as the lu-
minescence enhancement of this complex upon binding to
DNA is strongly dependent on the ionic strength. Cations
like Mg2+, usually also interacts in this way.25
3. 5. Metal-Drug Complexes 
DNA represents a fruitful target for metal comple-
xes as well. Transition metal complexes are known to
bind to DNA via both covalent and/or non-covalent
interactions. In covalent binding the labile ligand of the
complex is replaced by a nitrogen base of DNA such as
guanine N7. On the other hand, the non-covalent DNA
interactions include intercalative, electrostatic and groo-
ve (surface) binding of metal complexes along outside of
DNA helix, along major or minor groove. Very important
class of complexes that react with DNA are metal-drug
complexes. Among numerous drugs, particularly quino-
lone antibiotics are very often reported to form such com-
plexes.26 DNA can provide three distinctive binding sites
for quinolone metal complexes; namely, groove binding,
electrostatic binding to phosphate group and intercala-
tion.27,28 Related to the great biological role of the quino-
lone antibiotics in humans, this behaviour deserves our
attention. In synthesized ciprofloxacine complexes with
Mn2+, Fe3+, Co2+, Ni2+ and MoO2
2+,29 ciprofloxacin is de-
protonated and behave as bidentate ligand bound to the
metal ion through the pyridine oxygen and one carboxy-
late oxygen. Each metal ion is six-coordinated with geo-
metry around octahedronally distorted. Results showed
that these complexes can bind to DNA by both intercala-
tive and electrostatic binding mode. Other DNA–ciprof-
loxacine-metal complexes with Mg2+,30,31 Cu2+/Cu+,32 and
UO2
2+,33 as well as enrofloxacine-Cu2+ complex are also
reported.34 Magnesium-ciprofloxacine in aqueous me-
dium form colloidal particles that are believed to be in-
volved in specific binding to GC containing sequences,
most probably in the major groove of DNA. Mixed valen-
ce Cu2+/Cu+-ciprofloxacine complexes showed an intere-
sting DNA cleavage activity which exact mode of action
is not determined yet.32
3. 6. DNA–drug Interaction in Aqueous
Environment
In aqueous solution DNA is polyanion attracting po-
sitively charged counter ions (Na+, Ca2+ or Mg2+). Drug
molecules are also often charged and thus associated with
counter ions. The associated counter ions lie near the
charged groups and are also partially solvated. When the
binding occurs, it results in a displacement of solvent
from the binding site on both the DNA and drug. Also,
since there would be partial compensation of charges as
the DNA and the drug are oppositely charged, some coun-
ter ions would be released into the bulk solvent fully sol-
vated. Besides the counter ion effect, there are other inte-
ractions that must be considered, e.g. hydratation/dehy-
dratation process which occurs through drug–solvent
(hydration shell) and DNA–solvent interaction. Hydration
plays very important role in the stability of DNA molecu-
le, as well as DNA complex, since this process is believed
to be governing by the base sequence, also.
The binding process is also associated with some
structural deformation and adaptation of the DNA as well
as the drug molecule, in order to accommodate each other.
All these processes are associated with some enthalpic
and entropic changes that lead to the binding free energy
changes. It is confirmed that DNA double helix structure
is more stable when complexated with intercalating
agents, and the obtained complex shows a reduced heat of
denaturation compared to bare DNA. Since no covalent
bond formation is involved, the binding can be considered
as an equilibrium process, and the corresponding equili-
brium constants can be determined by measuring the free
and bound fraction of drug.
4. Analytical Techniques for Detection
DNA–drug Interaction
The aim of the contemporary research is to link
measurable biophysical parameters with cytotoxicity, and
to correlate the antitumor activity of the drug with its ca-
pability to intercalate into DNA double helix structure.
Detection and explanation of the arise changes is a gro-
wing challenge and a basis for application of the renewed
analytical techniques and methodologies for these cau-
ses. Large number of techniques is used to investigate
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DNA–drug interactions from classical UV-VIS spectros-
copy, along with 2D and 3D NMR spectroscopy, all the
way to most recent optical and electrochemical biosen-
sors.
4. 1. Optical Methods
The DNA–drug interaction can be detected by UV-
Vis absorption spectroscopy by measuring the changes
in the absorption properties of the drug or the DNA mole-
cules. The UV–Vis absorption spectrum of DNA exhibits
a broad band (200–350 nm) in the UV region with a ma-
ximum at 260 nm. This maximum is a consequence of the
chromophoric groups in purine and pyrimidine moieties
responsible for the electronic transitions. Slight changes
in the absorption maximum and the molar absorptivity
can occur with the variations in pH or ionic strength of
the media. DNA–drug interactions can be studied by
comparison of UV–Vis absorption spectra of the free
drug and DNA–drug complexes, which are usually diffe-
rent. The binding with DNA through intercalation usually
results in hypochromism and hypsochromism (blue shift)
or bathochromism (red shift). As a consequence of inter-
calative mode of binding that includes a stacking interac-
tion between an aromatic chromophore and the base pair
of DNA, the extent of the hypochromism consistent with
the strength of intercalative interaction can be obser-
ved.35–37
In the case of electrostatic attraction between the
compound and DNA, hyperchromic effect is observed that
reflects the changes of DNA conformation and structure
after the DNA–drug interaction has occurred. The hyperc-
hromic effect results in increase of absorbance of DNA
upon denaturation. When the DNA double helix is treated
with denaturing agents, the interaction force holding the
double helical structure is disrupted. The double helix
then separates into two single strands which are in the ran-
dom coiled conformation. At this time, the base–base inte-
raction will be reduced, increasing the UV absorbance of
DNA solution because many bases are in free form and do
not form hydrogen bonds with complementary bases. As a
result, the absorbance for single-stranded DNA (ss-DNA)
will be 40% higher than that for double stranded DNA
(ds-DNA) at the same concentration. Furthermore, the
hyperchromic effect arises mainly due to the presence of
charged cations which bind to DNA via electrostatic at-
traction to the phosphate group of DNA backbone and
thereby causing a contraction and overall damage to the
secondary structure of DNA.38
Based upon the variation in absorbance, the intrinsic
binding constant/association constant (K) of the drug with
DNA can be determined according to Benesi–Hildebrand
equation:39
(1)
where K is the binding/association constant, A0 and A are
the absorbancies of the drug and its complex with DNA,
respectively, and ε0 and ε are the absorption coefficients of
the drug and the drug–DNA complex, respectively. The
binding constant can be obtained from the intercept-to-
slope ratios of A0/(A – A0) vs. 1/[DNA] plots.
Many drug–DNA interactions are investigated by
analysing the above mentioned changes in absorption
spectra. The binding of three potential antibacterial
agents: Bu3SnL, Cy3SnL and Ph3SnL to DNA caused a
progressive blue shift of 10, 8 and 4 nm, respectively. The
peculiar hypochromism observed here is attributed to the
intercalation of these drugs into the DNA base pairs. The
reported binding constant values for these compounds are
ranged from 2.30 × 103 to 6.05 × 103 M–1. The highest va-
lue of K was observed for the Bu3SnL due to additional
hydrophobic nature of butyl group interacting with the ba-
ses of DNA.40 The interaction of daunorubicin with calf
thymus DNA (ct-DNA) has been investigated with the use
of methylene blue dye as a spectral probe by the applica-
tion of UV–Vis spectrophotometry, spectrofluorometry
and voltammetry. The results showed that both daunorubi-
cin and methylene blue molecules could intercalate into
the double helix of DNA.41 The thermodynamic parame-
ters were also calculated and suggested that hydrophobic
force might play a major role in the binding of daunorubi-
cin to ct-DNA.42
Based on electrochemical and spectroscopic results
reported by Kalanur at al.,43 the interaction between the
anticancer drug gemcitabine hydrochloride (GMB) and
DNA is suggested to be the groove binding. With the addi-
tion of increasing amounts of DNA the absorbance of
GMB increased at 207, 232, 248 and 283 nm (with red
shift at 207 and 248 nm), while those at 331 nm decreased
slightly. The high value of the binding constant, K = 1.97
× 106 M–1 suggests the strong interaction between drug
and DNA.
11-Phenyl-substituted indoloquinolines have been
found to exhibit significant antiproliferative potency in
cancer cells but to show only moderate affinity toward ge-
nomic double-helical DNA. In the study of Riechert-
Krause at all.,44 parallel and antiparallel triple-helical
DNA targets are employed to evaluate the triplex binding
of indoloquinoline ligands. Compared to parallel triple-
xes, an antiparallel triplex with a GT-containing third
strand constitutes a preferred target for the indoloquinoli-
ne drug. On the basis of pH-dependent titration experi-
ments and the results obtained with Job’s method of conti-
nuous variation, the binding of the drug and the stoichio-
metry of the complex was found to be pH strongly depen-
dent.
The interaction of doxorubicin with polynucleotides
and calf thymus DNA has been studied by several spec-
troscopic techniques in phosphate buffer aqueous solu-
tions.45 Obtained data showed that intercalation is the pre-
vailing mode of interaction, and also reveals that the inte-
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raction with AT-rich regions leads to the transfer of excita-
tion energy to doxorubicin.
Multi-spectroscopic methods including resonance
light scattering (RLS), ultraviolet spectra (UV), fluores-
cence spectra, 1H NMR spectroscopy, coupled with ther-
mo-denaturation experiments were used to study the inte-
raction of antitumor drug tamoxifen with calf thymus
DNA.46 The interaction caused a significant enhancement
of RLS intensity, the hyperchromic effect, red shift of ab-
sorption spectra and the fluorescence quenching of tamo-
xifen, indicating the inserting interaction between tamoxi-
fen and ct-DNA.
Recently, molecular docking and QSAR studies are
carried out for the investigation of interactions between
drugs and DNA. Eleven antitumor drugs (Doxorubicin,
Epirubicin, Cisplatin, Fluorouracil, Daunorubicin, Carbo-
platin, Etopside, Cyclophosphamide, Dactinomycine,
Dactinomycine and Mitoxantrone) are analyzed in the
work of Perveen and coauthors.47 Variation in spectral
profile of these drugs on the addition of DNA was used to
determine the values of formation constant (Kf) which is
an indicator of the binding strength of the drug with DNA.
Spectrophotometric studies are also used for systematic
study of DNA binding properties of irinotecan (CPT-11)
including binding constant, thermodynamic parameters,
and thermal denaturation. The binding of CPT-11 to ds-
DNA is quite strong as indicated by its remarkable hypoc-
hromicity, equilibrium binding constant and large positive
enthalpy and entropy changes.48
The study of the metal (Mn2+, Fe3+, Co2+, Ni2+ and
MoO2
2+) complexes of the antibacterial agent ciprofloxa-
cin (CF) interaction with ct-DNA performed with UV
spectroscopy revealed that all investigated complexes
could bind to DNA.29 In combination with cyclic voltam-
metry the authors showed that Fe-CF complex exhibits
much higher binding constant then other complexes.
Complexes Mn-CF, Fe-CF and Mo-CF bind to DNA by
both intercalation and electrostatic interaction, Ni-CF on-
ly by the intercalative mode and Co-CF can bind to DNA
by electrostatic interaction.
Fluorescence spectroscopy is probably one of the most
commonly used techniques to study interactions between
small ligand molecules and DNA. The advantages of mo-
lecular fluorescence over other techniques are its high
sensitivity, large linear concentration range and selecti-
vity. The most intense and the most useful fluorescence is
found in compounds containing aromatic functional
groups with low-energy π→π transition levels. Com-
pounds containing aliphatic and alicyclic carbonyl struc-
tures or highly conjugated double-bond structures may al-
so show fluorescence, but the number of these transitions
is small compared with those in aromatic systems.49
The orientation of fluorophoric ligands and their
closeness to the DNA pairs of bases can be studied by
fluorescence anisotropy or fluorescence resonance energy
transfer.50–52 Fluorescence quenching experiments give
additional information concerning the localization of the
drugs and their mode of interaction with DNA.53 Fluores-
cence quenching refers to any process that decreases the
fluorescence intensity of a sample. A variety of molecular
interactions, such as excited-state reactions, molecular
rearrangements, energy transfer and complex formation,
can result in quenching. Quenching of the fluorescence is
described by the Stern–Volmer equation49
(2)
where I0 is the fluorescence intensity in the absence of
quencher while I is the fluorescence intensity in the pre-
sence of quencher, and [Q] is the concentration of the
quencher. 
Fluorescence emission is very sensitive to the envi-
ronment, and hence the fluorophore transfer from high to
low polarity environments usually causes spectral shifts
(10–20 nm) in the excitation and emission spectra of
drugs.50 Interaction with DNA usually causes a significant
enhancement of the fluorescence intensity as a conse-
quence of different factors.54
Thus, in the case of intercalating drugs, the molecu-
les are inserted into the base stack of the helix. The rota-
tion of the free molecules favors the radiationless deacti-
vation of the excited states, but if the drugs are bound to
DNA the deactivation through fluorescence emission is
favored, and a significant increase in the fluorescence
emission is normally observed. In the case when groove
binding agents,55,56 electrostatic,57 hydrogen bonding58 or
hydrophobic interactions are involved, and the molecules
are close to the sugar-phosphate backbone, it is possible to
observe a decrease in the fluorescence intensity in the pre-
sence of DNA.59 In the presence of quencher, in the case
of intercalating agents the reduction in the Stern–Volmer
quenching constant (KSV) values is observed. KSV values
were obtained from the slope of the plot of I0/I vs. [DNA]
for several drugs.53,60
Different drugs were analyzed by spectrofluorime-
tric method with the aim to determine the binding mode,
quenching constant and thermodynamic constants. Pazuf-
loxacin, a new fluoroquinolone antibiotic, interacts with
ct-DNA in the mode of groove binding,61 and alkaloid Co-
deine, analgesic similar to morphine with uses similar to
morphine, combines with the groove of nucleic acids
through hydrogen bond or van der Waals force.62 Other al-
kaloids were also successfully studied using fluorescent
spectra.63
Ethidium bromide (EB) is a common fluorophore
that bind to DNA. The fluorescence of EB increases in the
presence of DNA, due to its strong intercalation between
the adjacent ct-DNA base pairs. It was previously reported
that the enhanced fluorescence can be quenched by the
addition of a second molecule. Thus if the second molecu-
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le intercalates into DNA, it leads to a decrease in the fluo-
rescence intensity of the EB–DNA because it will compe-
te with EB in binding with DNA. The extent of fluores-
cence quenching of EB bound to ct-DNA can be used to
determine the extent of binding between the second mole-
cule and ct-DNA.64–66 The binding mode of diacetylcurcu-
min (DAC), a synthetic derivative with promising activity
in threatening diseases like AIDS and cancer, was analy-
zed by competitive binding between ethidium bromide
(EB) and DAC for ct-DNA. DAC was found to be a minor
groove binder with a preference for the A-T region com-
pared to the G-C region.67
Competitive binding studies of metal (Mn2+, Fe3+,
Co2+, Ni2+ and MoO2
2+) complexes of the antibacterial
agent ciprofloxacin with EB showed that the complexes
exhibit the ability to displace EB from the EB–DNA com-
plex.29 EB shows a single monomeric peak at 480nm. On
adding ct-DNA its spectrum was changed showing the
red-shifted absorption peak from 480 to 488 nm and signi-
ficant decrease of the absorbance due to the formation of
EB–DNA complex by intercalation. Addition of a second
molecule, i.e. metal-ciprofloxacin complex, gradually dis-
places EB from the EB–DNA complex resulting in an in-
crease of the absorbance of the free EB. These results ex-
plained the ability of each complex to gradually displace
the DNA-bound EB, suggesting its strong competition
with EB for the intercalative binding site.
Infrared spectroscopy (IR) has been widely used for the
structural analysis of DNA because it can distinguish
among A-, B-, and Z-forms of DNA, triple stranded heli-
ces, and other structural modifications. It has also been a
useful tool to study interactions of nucleic acids with
drugs and the effects of such interactions in the structure
of DNA, providing some insights about the mechanism of
drug action. A major advantage is that samples can be
analyzed in different aggregation states, i.e., as solids or
crystals, and also in solution, making it possible to estab-
lish a comparison with results from other techniques. In
addition, small quantities of sample are needed and col-
lection of spectra is not time consuming. The characteri-
stic IR bands of nucleic acids have been compiled and dis-
cussed.68 Four regions are considered, each one contai-
ning marker bands reflecting either nucleic acid interac-
tions and/or conformations. Approximate position of IR
band regions are as follows: 1800–1500 cm–1 region, sen-
sitive to effects of base pairing and base stacking;
1500–1250 cm–1 region, sensitive to glycosidic bond rota-
tion, backbone conformation and sugar pucker;
1250–1000 cm–1 region, sensitive to backbone conforma-
tion and 1000–800 cm–1 region, sensitive to sugar confor-
mation.
The infrared spectra of three different parallel-
stranded DNAs (ps-DNA) have been studied by Fritzsche
and co-authors.69 They have used ps-DNAs and compared
them with their antiparallel-stranded (aps) reference du-
plexes in a conventional B-DNA conformation. Signifi-
cant differences have been found in the region of the
thymine C=O stretching vibrations. They also showed that
the interaction with three drugs known to bind in the mi-
nor groove of aps-DNA (netropsin, distamycin A and
Hoechst 33258) induces shifts of the C=O stretching vi-
brations of ps-DNA even at low ratio of drug per DNA ba-
se pair. Those results suggest a conformational change of
the ps-DNA and can be used to optimize the DNA–drug
interaction.
Fourier transform infrared (FTIR) spectroscopy has
been used alone or supporting other techniques to deter-
mine drug binding sites and sequence preference, as well
as conformational changes due to drug-DNA interac-
tion.70,71 FTIR with self-deconvolution and second-deriva-
tive resolution enhancement were used to determine the
drug binding mode, binding constant and the protein se-
condary structure in the presence of taxol in aqueous solu-
tion.72 The observed spectral changes indicate a partial
unfolding of the protein structure, in the presence of taxol
in aqueous solution. In another research73 FTIR difference
spectroscopy method was used to characterize the nature
of taxol–DNA interaction and to determine the taxol bin-
ding site, the binding constant, sequence selectivity, helix
stability and biopolymer secondary structure in the taxol-
DNA complexes in vitro.
5-Fluorouracil (5FU) is an anticancer chemothera-
peutic drug which exerts cytotoxic effect by inhibiting
cellular DNA replication. The binding of 5FU with DNA
results in structural and conformational changes on DNA
duplex. FTIR spectroscopic results74 revealed that interca-
lation is the primary mode of interaction between 5FU
and nitrogenous bases of the nucleic acid. The binding
constant was found to be 9.7 × 104 M–1; which is indicati-
ve of moderate type of interaction between 5FU and DNA
duplex. Furthermore, the authors showed that 5FU di-
sturbs native B-conformation of DNA though, DNA re-
mains in its B conformation even at higher concentrations
of 5FU. Similar results were obtain when FTIR spectros-
copy and molecular docking studies were employed to in-
vestigate chlorambucil anticancer drug interaction with
DNA.75
Multispectroscopic studies of paeoniflor 76 and mi-
toxantrone 77 interactions with calf-thymus DNA determi-
ned the modes of their binding. The results suggested that
paeoniflorin molecules could bind to DNA via groove
binding, while overall spectroscopic analysis revealed the
intercalation of mitoxantrone between the DNA base pairs
along with its external binding with phosphate–sugar
backbone.
Nuclear Magnetic Resonance (NMR) is based on the
fact that an atomic nucleus with odd number of protons or
neutrons has a property called nuclear spin that will align
with an applied magnetic field. The degree of this align-
ment depends not only on the strength of the magnetic
564 Acta Chim. Slov. 2014, 61, 555–573
Aleksi} and Kapetanovi}:  An Overview of the Optical and Electrochemical Methods   ...
field, but also on the type of nucleus and its chemical en-
vironment. Each magnetically active nucleus is characte-
rized by chemical shift, multiplicity, J-couplings, relaxa-
tion data and Nuclear Overhauser Effect (NOE), parame-
ters that can be used to obtain detailed structural informa-
tion about the molecule under study. NMR experiments
can be performed at different temperatures, solvents, pH
values, ionic strengths and dielectric constants.
Most common atomic nuclei available for the study
of DNA are 1H, 13C, 15N and 31P. Among them 31P NMR is
especially useful for studying the effects of ligand binding
on the phosphate groups of DNA. Chemical shifts of 31P
are sensitive to conformational changes in DNA, interca-
lating drugs cause downfield shift in the 31P signal, whe-
reas divalent cations cause upfield shifts. The characteri-
stic chemical shift for 1H NMR spectra of nucleic acids at
room temperature has been reported about twenty years
ago,78 and any significant change in the chemical shift is
attributed to the binding between ligand and DNA mole-
cule.78,79 The broadening of DNA 1H NMR resonances
upon addition of a suitable minor-groove binding com-
pound is usually taken as primary evidence of complex
formation.
The most useful 2D-NMR experiments are: Homo-
nuclear Shift Correlated Spectroscopy (COSY), which
provides scalar coupling information which is transmitted
over covalent bonds, and Nuclear Overhauser Enhance-
ment Spectroscopy (NOESY), which provides informa-
tion related to the spatial arrangements of atoms relative
to one another and can show whether the double-helical is
left or right handed.
Various DNA–drug complexes were studied using
NMR spectroscopy. Netropsin antibiotic was reported to
bind specifically on 5’-AATT sequence of DNA octamer
duplex (DNA-5) in the minor groove.80 The formation of
netropsin–DNA complex caused 13C-NMR chemical
shift. Mazzini et al.81 described berberine binding to AT-
rich sequences of DNA oligomer, and Park et al.82 have al-
so demonstrated the DNA-binding-induced 1H-NMR che-
mical shifts of berberine. In another study the same aut-
hors83 have used UV and 1H-NMR methods to show that
protoberberine interacts with the DNA duplex. However,
the structural evaluation of the drug–DNA complex was
not furnished.
In 2009, Mondelli group84 has discussed the interca-
lation complex of topopyrone between GC base pairs of
DNA, and Wu et al.85 have shown the intra-strand GG
cross-linked oxaliplatin complex with DNA. The interac-
tion of the antibiotic drug norfloxacin with double-stran-
ded DNA was studied by 1H NMR spectroscopy.86 A high-
ly selective broadening of the imino proton resonances as-
signed to central CpG steps was observed after addition of
drug, indicating an intercalation-like interaction. In the sa-
me paper, using two-dimensional-NOESY spectra, aut-
hors reported that the planar two-ring system of nor-
floxacin partially intercalates into CpG steps and that the
drug also exhibits non-specific groove binding. Another
research group used 1H NMR spectroscopy (500 MHz) to
quantify the complexation of the norfloxacin with DNA in
the presence of caffeine.87 They succeeded to determine
the equilibrium parameters (induced chemical shifts, as-
sociation constants, enthalpy and entropy) of the two and
three-component mixtures. Investigations of the competi-
tive binding of norfloxacin and caffeine with DNA show
that the dominant mechanism influencing the affinity of
norfloxacin with DNA is the displacement of bound norf-
loxacin molecules from DNA due to caffeine–DNA com-
plexation (i.e. the protector action of caffeine). Similar re-
sults were obtained upon the complexation of three diffe-
rent anthracycline antitumour drugs with DNA in the pre-
sence of caffeine.88
The binding of mitoxantrone, a promising antitumor
drug with reduced cardiotoxicity, to DNA has been stu-
died by proton and phosphorous-31 nuclear magnetic re-
sonance spectroscopy.89 The stoichiometry reveals that
1:1 and 2:1 mitoxantrone–d(ATCGAT)2 complexes are
formed in solution. Authors suggest that mitoxantrone
binds as a monomer at either or both ends of hexamer ex-
ternally with side chains interacting specifically with
DNA. This finding seems to be relevant to the understan-
ding of pharmacological action of drug. Solid-state
31P–19F REDOR nuclear magnetic resonance (NMR) ex-
periments were performed to monitor changes in minor
groove width of the selected oligonucleotide upon binding
of the drug distamycin. In the hydrated solid-state sample,
the minor groove width for the unbound DNA was 9.4 Å.
Binding of a single drug molecule caused a 2.4 Å decrea-
se in groove width. Subsequent addition of a second drug
molecule results in a larger conformational change, ex-
panding this minor groove width to 13.6 Å. These results
demonstrate the ability of solid-state NMR to provide the
direct spectroscopic measurement of minor groove width
in nucleic acids.90 The methodological approach of 23Na
NMR spectroscopy to the study of the structure and dyna-
mics of the DNA molecule was reviewed by Mariccola at.
al.91 In particular, the application of the 23Na NMR qua-
drupolar relaxation to investigate the perturbations on the
polyion surface due to exogenous agents was discussed. 
Circular and linear dichroism spectroscopies are useful
techniques for studying non-covalent drug-DNA interac-
tions, which affect the electronic structure of the molecu-
les. Linear dichroism (LD) use polarized light and provi-
des structural information in terms of the relative orienta-
tion between the bound drug molecule and the DNA mo-
lecular long axis.92 LD spectroscopy involves measuring
the difference in absorption of two linear polarizations of
light, which usually are parallel and perpendicular to a
sample orientation direction. In contrast to LD which de-
pends only on the electric field vector, circular dichroism
(CD) depends on both electric and magnetic interactions
and provides additional structural details of the formed
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complex.92,93 CD signals of nucleic acids are observed in
the UV region between 200 and 300 nm. In general B
form of DNA has a positive signal, and A form tends to
exhibit a positive and more intense signal. In contrast, CD
of the left handed double helix of Z form DNA exhibits al-
most the reverse pattern to that of B form. These characte-
ristic features of the CD spectra are the most useful for
studding DNA conformational changes arising from drug
binding. When an achiral and chromophoric drug binds to
DNA, an induced circular dichroism (ICD) may appear
within the adsorption band of the asymmetrically pertur-
bed chromophore. On the other hand, DNA binding of a
chiral chromophoric drug may result in a CD change wit-
hin the absorption band of the drug as well as a CD chan-
ge in the absorption region of the DNA due to the pertur-
bations of structures with already optically active transi-
tion moments. Third possibility is DNA binding of a chi-
ral drug which is silent because it contains weak UV-Vis
chromophores which may give rise to CD changes within
the absorption bands of the DNA only. The observation of
an ICD immediately reveals that the drug actually binds to
DNA, while its sign provides qualitative information
about the binding mode: whether it is an intercalator or a
groove binder, or binds on the outside of the polyphospha-
te backbone. In general, a strong, positive ICD is typical
of a minor groove binder, while intercalators usually exhi-
bit negative and weaker ICDs.
Circular dichroism was used to study the interaction
of diacetylcurcumin (DAC) with ct-DNA,67 and did not
reveal any unwinding of the DNA helix on interaction
with DAC, implying no conformational changes. Also,
circular dichroism binding isotherms give stoichiometry
of 0.25, and 0.5 for anticancer drug mitoxantrone molecu-
les binding per duplex.94 The CD spectra show blue shift
and change in intensity of bands accompanied by appea-
rance of induced bands. The results suggest stacking of
aromatic chromophore of mitoxantrone with terminal ba-
se pair of DNA strand forming a sandwiched structure of
mitoxantrone between four and two duplex molecules.
Neomycin is reported to be the most effective ami-
noglycoside in stabilizing a DNA triple helix without any
effect on the DNA duplex. Triplex stabilization by neomy-
cin is salt and pH dependent. CD binding studies indicate
∼5-7 base triplets per drug apparent binding site, depen-
ding upon the structure of the triplex. The novel selectivity
of neomycin is suggested to be a function of its charge and
shape complementarity to the triplex W-H groove.95
Studies on the binding affinity of anticancer drug
mitoxantrone to chromatin, DNA and histone proteins we-
re performed employing UV/Vis, fluorescence, CD spec-
troscopy, gel electrophoresis and equilibrium dialysis
techniques.96 CD and fluorescence analysis showed that
mitoxantrone interacts strongly with histone proteins in
solution making structural changes in the molecule. The
higher binding affinity of mitoxantrone to chromatin com-
pared to DNA has been suggested, implying that the histo-
ne proteins may play an important role in the chroma-
tin–mitoxantrone interaction process.
Viscosity measurements
Optical methods provide many crucial information about
DNA–drug interaction, but still sometimes they do not of-
fer sufficient clues to support a binding model. In the ab-
sence of the crystallographic structural data, viscosity
measurements represents critical test of a DNA binding
model in the solution. A viscosity measurement is
hydrodynamic experiment that is sensitive to the change
in molecule length. During the process of intercalation the
lengthening of the DNA helix occurred since base pairs
are separated to accommodate the bound ligand, leading
to the increase of DNA viscosity. On the other hand, in the
case of electrostatic interaction (out-binding mode) the
compactness and aggregation of DNA may occur. The ag-
gregation reduces the number of independently moving
DNA molecules which results in lowering the solution
viscosity. Groove binding drugs also induce a decrease in
DNA solution viscosity. Such event is described by a bend
or loop within the DNA helix, shortening the overall heli-
cal length.97
Viscosity measurements are performed using Os-
wald or Ubbelohde type viscometer measuring the flow ti-
me of the sample solutions after reaching the thermal
equilibrium. The relative viscosity is calculated according
to equation η ∼ (t – t0)/t, where t, and t0 represents flow ti-
mes of the sample and buffer solution respectively, and
data are usually presented as (η/η0)1/3 versus DNA/drug
binding ratio, where η is the viscosity of the DNA in the
presence and η0 in the absence of the drug.
Viscosity measurements are often performed along
with other optical methods. A class of novel carboline an-
ti-tumor agents was analyzed.98 Relative viscosity of the
drug/DNA solutions in the ratios of 0–0.36 was measured
and results indicate its increase, what is considered as a
result of the intercalation. The same result was observed
for polypyridyl ruthenium(II) complexes,99 and ciproflo-
xacin drug based metal complexes.100
Neomycin is shown to be the first molecule that can
selectively stabilize DNA triplex structures (polynucleoti-
des, small homopolymer, as well as mixed base triplexes).
Based on viscosimetric studies, this stabilization is shown
to be based on neomycin’s ability to bind triplexes in the
groove with high affinity.95 The interaction of potential
anticancer drug, 4-nitrophenylferrocene (NFC) with DNA
was also studied by viscosity measurements.101 The plot
η/η0 with increasing concentration of NFC reveals negati-
ve change. Authors suggested that such a behavior is due
to the electrostatic interaction that may cause the com-
pactness and aggregation of DNA. Very interesting beha-
vior was observed with acridin derivative, ACMA, potent
antitumor agent.102 From the viscosity studies it was
shown that its apparent binding site depends upon the dif-
ferent structural or compositional domains (e.g., AT-rich
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vs. GC-rich), which may display different affinity with the
drug. ACMA interacts with the A–T and G–C bases quite
differently; interaction with AT-rich domains is intercala-
tion, while the interaction with GC-rich domains lead to
the formation of two distinct complexes (partially interca-
lated and groove binding), depending on the ACMA con-
tent.
4. 2. Electrochemical Biosensors
During the last decade of the 20th century, DNA oli-
gomers have been utilized as selective bio-recognition
elements in new group of affinity biosensors. These so
called DNA-based biosensors possess specificity of the
response taking advantage of the bioaffinity properties of
DNA. However, in contrast to conventional enzyme- and
imuno-sensors, the DNA biosensors are mostly used for
the investigation of interactions of DNA itself rather than
for typical determination of the concentration of an analy-
te.103–105
According to International Union of Pure and Ap-
plied Chemistry (IUPAC) an electrochemical biosensor is
a self-contained integrated device, which is capable of
providing specific quantitative or semi-quantitative analy-
tical information using a biological recognition element
(biochemical receptor) which is retained in direct spatial
contact with an electrochemical transduction element.106
Simply, it can be characterized as a devise that integrates
DNA as the biological recognition element and an electro-
de as the physicochemical transducer. It is often presented
as an electrode chemically modified by nucleic acid. Ad-
vantages and successful use of the electrochemical DNA
biosensors have been reported and reviewed in numerous
papers.107–113
Operation Principles
The signal obtained at the modified electrode surface is
transduced into the electrical signal. The measurement
can be carried out both amperometrically and potentiome-
trically. In amperometric measurement, an external poten-
tial is applied to oxidize or reduce an electrochemically
active compound at its intrinsic redox potential, and the
current produced during the process is measured. In po-
tentiometric measurements, equilibrium is reached at the
electrode surface without the need of the external poten-
tial, and as a consequence, the equilibrium potential bet-
ween the electrode and the measured solution is generated
and recorded.106,114 The possibility of setting the working
potential to the specific redox value of the analyte of inte-
rest provides the greater selectivity for the amperometric
detection. The procedure usually includes the following
three steps: 1) DNA immobilization on the electrode sur-
face, 2) dipping the electrode into analyte solution, and 3)
measuring of the current response. The measured current
intensity depends on the concentration of the analyte fol-
lowing the Cottrel’s equation:
(3)
where A represents the area of the electrode, D is diffusion
coefficient, C is concentration of the analyte, t is time du-
ring which the measurement is performed, and n is the
number of exchanged electrons in the electrode process.
The electrode used as transducer element can be ma-
de up from different materials such as platinum, gold,
mercury, pyrolytic graphite, glassy carbon or carbon pa-
ste. The use of solid conductors dispersed into polymeric
nonconducting matrices – composites and nanostructured
materials is growing over the last years. The last class of
materials such as metal nanoparticles, magnetic nanopar-
ticles or carbon nanotubes possesses very attractive featu-
res. The large surface and characteristic conducting pro-
perties allow them to achieve better response times, higher
sensitivity and improved specificity.115–117
Depending on the electrode material, DNA can be
immobilized on the electrode surface using different tech-
niques: physical adsorption, electrochemical adsorption,
covalent binding, the use of avidid/biotin complex, or the
electropolymerized monomers like pyrrole, with the role
of trapping the DNA molecules and binding them to the
electrode. 
Detection Principles
Regardless to the DNA immobilization technique the fun-
damental principle of the detection is based on the fact
that the electrode detects the change at the DNA molecu-
le. The resulting change may be due to the change in DNA
concentration, orientation (conformation) or structure,
caused by damage or denaturation. On the other hand,
modification of the signal can also be caused by the non-
covalent interactions of DNA with different ligands that
lead to hybridization, association or complex formation.
The most widely used substances that reversible bind to
DNA are electroactive intercalators, and by measuring the
change in redox signals derived from an electroactive in-
tercalator, the interaction can be followed (Figure 3). The
Figure 3. Schematic presentation of the change in the intercalator
redox signal derived upon the interaction with DNA
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third type of interactions that can be registered by elec-
trochemical biosensor are the irreversible interactions
among electroactive substances covalently bound to ds-
DNA (double-stranded, native DNA), used mostly for in-
creasing selectivity of analytical determination of DNA.
4. 2. 1. Electrochemical Activity of DNA 
When nucleic acids interact with electrodes, they are
usually strongly adsorbed. The adsorbed nucleic acid un-
dergoes charge-transfer reactions, producing signals that
can provide information about their concentration, chan-
ges in structure and orientation. Electrochemical activity
of DNA is a consequence of the redox properties of nuc-
leobases. Guanine and adenine residues are oxidized at
carbon electrodes, while cytosine and adenine residues are
reduced at mercury electrodes, in aqueous solutions at
neutral pH. Thymine (T) is reduced only in non-aqueous
media at highly negative potentials.118–123 Electroactive
groups that undergoes oxidation or reduction processes
are presented in Figure 1.
Oxidation of guanine at glassy carbon electrodes oc-
curs in two consecutive irreversible steps, yielding peaks
at + 0.8 V and + 0.95 V vs. Ag/AgCl.122,124 Adenine oxida-
tion at glassy carbon electrodes is also irreversible, and
occurs in three steps.123 In cyclic voltammogram of adeni-
ne, two peaks are observable, at + 1.05 V and + 1.12 V vs.
Ag/AgCl, and the third one, is detected after several
scans, and corresponds to oxidation of adenine electroac-
tive products formed at the electrode surface.124 DNA oxi-
dation can be followed at other carbon electrodes, such as
pyrolytic graphite, carbon paste, modified carbon electro-
des, as well as with the tin-oxide electrode.
At neutral and weakly acidic pH, adenine and cyto-
sine residues in DNA produce reduction signals at mer-
cury-based electrodes close to –1.4 V vs. Ag/AgCl, and in
cyclic modes guanine yields an anodic signal, at about
–0.3 V vs. Ag/AgCl, due to the oxidation of its reduction
product back to guanine.119 The pH of the solution has an
important role in the detection process, since protonation
of bases is involved in the electrode process. Nucleic acids
strongly adsorb on electrodes, especially on mercury and
carbon. Ideally smooth and highly reproducible surface of
liquid mercury is very well suited for alternating current
(ac) impedance measurements, which can provide infor-
mation about DNA adsorption/desorption properties. This
adsorption/desorption behaviour of DNA depends on the
structure of the DNA molecules, and its orientation on the
electrode surface. Reduction signals of adenine and cyto-
sine are strongly influenced by DNA structure. For exam-
ple, in differential pulse polarography, the reduction peak
of native ds-DNA is almost two orders of magnitude smal-
ler than the peak of denatured, ss-DNA. Also the non-Fa-
radaic capacity signals are highly sensitive to changes in
DNA structure, and can provide information about the ba-
ses interactions with the electrode.125 Since the electroc-
hemical signals are strongly influenced by the DNA struc-
ture, mercury electrodes are more suitable for studies of
DNA structural transitions and local conformational chan-
ges. Experiments with mercury electrodes have identified
single-strand interruptions in linear and circular DNA mo-
lecules, differences in the superhelix density of supercoi-
led DNAs, and superhelix density dependent structural
transitions in DNA.126,127 According to all this, electroche-
mical analysis of DNA can, in principle, be performed
without introducing any labels and additional reagents in-
to DNA. This kind of detection principle is often called
Label-free technique and it is based on electrochemical
and surface activity of DNA.128,129 Electrochemical reduc-
tion and oxidation of nucleobases are irreversible and do
not allow reusability of these kind of biosensors.
4. 2. 2. Non-covalent Drug–DNA Interaction
The use of DNA redox indicators is an alternative
technique used to detect the presence and interaction
events of immobilized DNA such as hybridization, dama-
ge, and association with another substance. The redox in-
dicators usually show their electrochemical response at
potentials different enough from the nucleobases, which is
often reversible. Some of the indicators interact with DNA
through electrostatic forces,130 while others are present
“free” in the solution phase. Special kind of redox indica-
tors are the intercalators. Due to the accumulation within
the immobilized ds-DNA layer, the bound indicator exhi-
bits an increased voltammetric response. 
The most commonly used redox indicators are
drugs, especially anticancer agents. For example dau-
nomycin can be oxidized at low potentials and high cur-
rent density on a basal plane pyrolytic graphite electrode
with an adsorbed DNA probe.131 This kind of modified
electrode detects electrochemical signal derived from an
intercalator non-specifically bind to DNA. Voltammetric
characteristics such as anodic and cathodic voltammetric
peak potential and current of different drugs obtained at
modified graphite electrode are presented in Table 2.131
Glassy carbon electrode was used for electrochemi-
cal study of in situ anticancer drug adriamycin oxidative
damage to DNA.132 In the study of Tiware et al.,133 DNA
modified glassy carbon fiber electrodes were used to study
the interaction between the adriamycin and DNA. They re-
ported a formation of an adriamycin radical which is able
to oxidize the guanine in the ds-DNA, thereby causing the
decrease in the guanine oxidation peak. Voltammetric mea-
surements on glassy carbon electrode showed that antileu-
kemia drug glivec binds to ds-DNA and leads to modifica-
tions in the ds-DNA structure, recognized through changes
of the anodic oxidation peaks of guanine and adenine ba-
ses.134 Using the same electrode, the decrease of the ds-
DNA oxidation peaks are detected upon the interaction of
microcystin-LR and nodularin with DNA due to the aggre-
gation of DNA strands which may cause the mutations in
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the ds-DNA during the replication process.135 Similar re-
search involving another anticancer drugs, epirubicin136
and mitoxantrone,137 reported a decrease in peak current
obtained at modified carbon paste electrode upon the inte-
raction of these drugs with DNA. Recently, an anodically
activated pencil graphite electrode (PGE) was employed
for investigating the mechanism of the interaction between
the anticancer drug leuprolide and fish sperm ds-DNA, im-
mobilized into the electrode surface.138
Mercury based electrodes are also used to investiga-
te intercalation reactions mostly based on reduction pro-
cesses.130,139,140 It is known that some intercalators could
distinguish between ds-DNA and ss-DNA. Data obtained
by voltammetric experiments using both the ss-DNA and
ds-DNA modified electrode showed the type of binding of
the intercalators. Bard and co-authors141–143 reported that
positive shifts of the peak potential were observed in the
binding form via hydrophobic interactions (intercalation),
while electrostatic interactions led to negative shift. Elec-
trochemistry of anti-tumor drugs echinomycin,144 and
acridine,145 as well as nicotinic partial agonist varenicli-
ne,146 and their interaction with DNA were studied on
hanging mercury drop electrode. In all cases a formation
of drug–DNA complex was reported and the binding con-
stant values determined.
Several other electrodes have been exploited in these
studies. Among them modified gold surfaces are very often
used. The self-assembled monolayers (SAMs) of an azido-
hexane thiol derivative were prepared on the Au electrode,
and then used for the immobilization of ds-DNA and inve-
stigation of interactions of taxol, a very important antican-
cer drug, and DNA.147 This was done by monitoring the
guanine oxidation peak current. Sun at al.148 used dau-
nomycin intercalated into a ds-DNA as a biosensor to inve-
stigate the relation between peak current and the concen-
tration of the DNA at modified gold electrode.
Due to the recent progress in the analysis of nucleic
acids, peptides and proteins, the electrochemical methods
appear ready for application to sequence-specific and
nonspecific interactions of proteins with DNA. Peptides,
polyaminoacids and proteins produce a structure-sensitive
chronopotentiometric peak at mercury electrodes, which
is due to the catalytic hydrogen evolution reaction. This
characteristic reaction was used in the investigation of ba-
sic protein like histones, binding to DNA,149 as well as in
the research on the aggregation of α-synnuclein in Parkin-
son’s disease,150 and mutation of tumor suppressor pro-
teins p53.151
4. 2. 3. Covalent drug–DNA Interactions
Electrochemically active DNA labels (tracers) are
compounds covalently bound to DNA, which are used for
the DNA detection with improved analytical selectivity
and specifity.113,130,152 Most commonly used labels are
modified ferrocene,153 nitrophenyl and aminophenyl
groups, as well as osmium tetraoxide complexes with ni-
trogen ligands.154–156
There are number of drugs that interact covalently
with DNA molecule.9 Covalent binding in DNA is irrever-
sible and undoubtedly leads to complete inhibition of
DNA functions and subsequent cell death. The most fa-
mous covalent binder is cisplatin (Table 1), which is used
as an anticancer drug. The use of electrochemical techni-
ques for studying platinum–DNA interactions were repor-
ted by Brabec157 and by Erdem et al.,158 who studied the
binding of cisplatin and a cisplatin-like chemotherapeutic
agent to DNA which was coated on a wax- impregnated
graphite electrode and a pencil graphite electrode, respec-
tively, by using differential pulse voltammetry. Besides,
Oliveira-Brett et al. reported the electrochemical determi-
nation of carboplatin in serum using a DNA-modified
glassy carbon electrode.159
Mascini et al. have developed biosensors involving
binding of cisplatin, carboplatin, platinum bipy and oxali-
platin160–162 to double-stranded DNA immobilized on the
Table 2. Anodic and cathodic voltammetric peak potentials and currents of some intercalators in phosphate buf-
fer, pH 7.0 (working electrode pyrolytic graphite, reference electrode Ag/AgCl, v = 25 mVs–1).131
Intercalator Epa (mV) ipa (μA) Epc (mV) ipc (μA)
Anthracycline antibiotics
Daunomycin 446 2.06 394 0.34
Doxorubicin 440 3.81 391 0.41
Pirarubicin 446 1.47 389 0.26
Tetraccycline antibiotics
Tetracycline 674 1.88 – –
Doxycycline 663 2.79 – –
Minocycline 385 3.58 155 0.42
Others
7-Aminoactinomycin D 651 1.34 376 0.51
Propidium iodide 631 4.84 494 1.03
Quinacrine mustard 688 2.54 –73 0.32
Rifampicin 718 3.49 44 0.57
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surface of screen-printed electrodes (SPEs). These biosen-
sors use chronopotentiometry or square wave voltamme-
try (SWV), to rapidly and quantitatively measure the de-
crease of the oxidation peak of guanine. By calculating
the ratio between the area (or height) of the guanine oxi-
dation peak after interaction with the drug, and the area
obtained by DNA alone, the percent of guanine sites in
DNA that have not been modified by the interaction can
be estimated.
The attempt to use non-platinum metal complexes
as anticancer agents was initiated with an idea to find less
toxic and more specific drugs. Some ruthenium and tita-
nium complexes showed promising pharmacological pro-
perties as antitumor and antimetastatic agents. The inte-
raction of ruthenium(III) complex, NAMI-A, with ds-
DNA immobilized on screen-printed electrodes was stu-
died as a screening tool for in vitro DNA–drug interac-
tion.163 Titanium(IV) complex titanocene dichloride sho-
wed a lower degree of interaction with DNA than cisplatin
since the ionic interaction between Ti cation and external
phosphate backbone produces a minor effect on the oxida-
tion of G with respect to the direct coordination.164
This approach that has been successfully employed
for the study of the interaction between a series of antitu-
mor metallo-drugs and DNA offers information concer-
ning the reactivity of the metal complex, the effect of an-
ions acting as leaving ligands, the affinity of the generated
electrophilic agent to DNA, and the strength of perturba-
tion caused in the DNA chain by these metallo-drugs.
In the last decade, the use of nanostructured mate-
rials is spreading in the field of nanosensors. This class of
materials such as carbon nanotubes, magnetic nanopartic-
les or metal nanoparticles possesses very attractive featu-
res. Carbon nanotubes have recently attracted considerab-
le attention due to their unique structural, electronic, mec-
hanical and chemical properties.165 The large specific sur-
face and characteristic conducting properties allow them
to achieve better response times, higher sensitivity and
improved specificity.115 Aligned carbon nanotubes were
used to detect a DNA sequence characteristic for geneti-
cally modified organisms with sensitivity in the nanomo-
lar range.116 A combination of magnetic beads for immu-
nomagnetic separation and a later detection step using
magnetic graphite-epoxy composite electrode has been re-
cently employed for the detection of Salmonella in milk
with the very low limit of detection.117 Nanoparticles or
nanocrystals of gold, indium, zinc, cadmium or lead chal-
cogenides have been used as well.166
5. Conclusions
Having in mind that DNA is one of the most impor-
tant biomacromolecule, the possibility of detection and
explanation of the changes resulting upon its interaction
with chemotherapeutic drugs deserves a great attention.
It is very important to use the most advanced methods in
the analysis of drugs and toxic substances that may pro-
duce changes in DNA structure. The choice of the appro-
priate instrumental method allows the complete knowled-
ge of the nature and the type of the mentioned interaction. 
Compounds binding with DNA through intercala-
tion usually results in hypochromism and hypsochro-
mism (blue shift) or bathochromism (red shift) of the
UV–Vis absorption spectra. In case of electrostatic at-
traction between the compound and DNA, hyperchromic
effect is observed that reflects the changes of DNA con-
formation and structure. The advantage of molecular
fluorescence over other techniques is its high sensitivity,
large linear concentration range and selectivity. Interac-
tion with DNA usually causes a significant enhancement
of the fluorescence intensity. Fluorescence quenching ex-
periments give information concerning the localization of
the drugs and their mode of interaction with DNA. A ma-
jor advantage that the application of IR spectroscopy of-
fers is that samples can be analyzed in different aggrega-
tion states. Fourier transform infrared (FTIR) spectros-
copy has been used to determine drug binding sites and
sequence preference, as well as conformational changes
due to drug–DNA interaction. Chemical shifts in NMR
spectra are attributed to the binding between ligand and
DNA molecule and are sensitive to conformational chan-
ges. Intercalating drugs cause downfield shift, and the
broadening of DNA 1H NMR resonances upon addition
of a suitable minor-groove binding compound is usually
taken as primary evidence of complex formation. CD
spectra may distinguish between chiral and achiral drug
via an induced circular dichroism. The observation of an
ICD immediately reveals that the drug actually binds to
DNA, while its sign provides qualitative information
about the binding mode: a strong, positive ICD is typical
of a minor groove binder, while intercalators usually ex-
hibit negative and weaker ICDs. The fundamental princi-
ple of the electrochemical biosensor detection is based on
the fact that the electrode detects the change at the DNA
molecule. Upon the interaction with the drug, changes in
intensity and position of the voltammetric signals of both
drug and DNA may occur. Positive shifts of the peak po-
tential were observed in the binding form via hydropho-
bic interactions (intercalation), while electrostatic inte-
ractions led to negative shift.
The application of existing and development of new
techniques and methods aims to expand research limits re-
garding to DNA selectivity and bioaffinity towards the
drug, as well as for fundamental evaluation of effects of
their interaction.
Although all mentioned techniques show their own
specificity, their common aim is to correlate the measu-
rable biophysical parameters with cytotoxicity i.e. anti-
cancer activity of the drug, and to enforce the obtained
knowledge for design new DNA ligands for in vitro and in
vivo genetic diseases monitoring.
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Povzetek
[tevilne anorganske in organske spojine se lahko ve`ejo na DNA in tvorijo komplekse. Mednje sodijo tudi zdravilne
u~inkovine, {e posebno kemoterapevtiki. V tem prispevku je zbran pregled strukturnih zna~ilnosti DNA in vrst interak-
cij (kovalentne in nekovalentne) med DNA in zdravilnimi u~inkovinami. Kovalentna vezava u~inkovine je ireverzibilna
in vodi do popolne inhibicije delovanja DNA, kar posledi~no vodi do celi~ne smrti. Nekovalentna vezava je reverzibil-
na in temelji na osnovah molekulske prepoznave. Posebna pozornost je namenjena ugotavljanju specifi~nih vezavnih
mest na DNA za vezavo u~inkovin. Glede na strukturne zna~ilnosti so u~inkovine, ki se ve`ejo nekovalentno na DNA,
ve~inoma interkalatorji, lahko pa se ve`ejo tudi na veliko ali malo brazdo DNA.
Ko se tvori kompleks med u~inkovino in DNA, pride do delne modifikacije tako u~inkovine kot tudi same DNA. Zbran
je pregled metod za prou~evanje interakcij med DNA in u~inkovinami z namenom kako detektirati nastale spremembe
in interpretirati rezultate. S tem namenom se uporablja {tevilne spektroskopske metode kot so UV–Vis, fluorescenca, IR
in NMR, spektroskopije z uporabo polarizirane svetlobe, kot sta cirkularni in linearni dikroizem ter fluorescen~na ani-
zotropija ali resonanca. Razvoj elektrokemijskih DNA biosenzorjev odpira nova obzorja za uporabo zelo ob~utljivih in
selektivnih elektrokemijskih metod za detekcijo specifi~nih DNA interakcij. Predstavljeni rezultati podajajo pregled li-
terature s podro~ja omenjenih metod. S pomo~jo obravnavanih metod lahko ugotavljamo po{kodbe DNA, dolo~amo ve-
zavna mesta u~inkovin in preferen~ne sekvence, kot tudi konformacijske spremembe zaradi nastanka interakcij u~inko-
vina–DNA.
